# Semeia

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/semeia

- Industry: Software
- Headquarters: Paris, France
- Website: www.semeia.io
- Total disclosed funding: $4.5M
- Latest round: Series A (Nov 22, 2022)
- Investors on record: 3

## About

Based in Paris, France, and founded in 2017, Semeia SAS operates as a software development company. The company was founded by its CEO Pierre Hornus, Mathieu Godart, and President Daniel Szeftel. In February 2021, Semeia SAS raised EUR 3 million in venture funding from Banque des Territoires. In December 2022, Semeia SAS raised EUR 8 million in venture funding from MH Innov, Orange Ventures, and Banque des Territoires.

The product line of Semeia includes Nephro Wise, which is software that monitors the blood pressure and weight of patients; Mind Wise, which is software that monitors patients' mental and somatic health; Onco Wise, which is software that monitors breast cancer patients; Cardio Wise; Pneumo Wise; and Rheumato Wise.

The company plans to use the funds raised in February 2021 to support its platform expansion.

## Funding rounds

- Series A, Nov 22, 2022, $4.5M — Orange Ventures, Banque des Territoires, MH Innov

## Investors

- Orange Ventures — Series A
- Banque des Territoires — Series A
- MH Innov (https://capitalatlas.ai/funds/mh-innov) — Series A